US Stock MarketDetailed Quotes
BIOA BioAge Labs
- 4.300
- +0.200+4.88%
Close Dec 18 16:00 ET
- 4.450
- +0.150+3.49%
Pre 06:26 ET
154.15MMarket Cap-2.07P/E (TTM)
5.120High3.970Low4.71MVolume4.800Open4.100Pre Close20.96MTurnover44.90%Turnover RatioLossP/E (Static)35.85MShares26.62052wk High0.49P/B45.15MFloat Cap3.85052wk Low--Dividend TTM10.50MShs Float26.620Historical High--Div YieldTTM28.05%Amplitude3.850Historical Low4.445Avg Price1Lot Size
BioAge Labs Stock Forum
Sign in to post a comment
$BioAge Labs (BIOA.US)$ What will it take for this stock?
$BioAge Labs (BIOA.US)$
Bristol Myers Squibb will become solely responsible for the development and any subsequent commercialization of BAN1503 and BAN2803 and related products worldwide.
Bristol Myers Squibb will become solely responsible for the development and any subsequent commercialization of BAN1503 and BAN2803 and related products worldwide.
7
4
1
$BioAge Labs (BIOA.US)$
BioArctic announces global license agreement with Bristol Myers Squibb for BioArctic's PyroGlutamate-amyloid-beta antibody program
STOCKHOLM, Dec. 19, 2024 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that it has entered into a global exclusive license agreement with Bristol Myers Squibb (NYSE: BMY) for BioArctic's PyroGlutamate-amyloid-beta (PyroGlu-Aβ) antibody program, including BAN1503 and BAN2803, whereof the latter includes BioAr...
BioArctic announces global license agreement with Bristol Myers Squibb for BioArctic's PyroGlutamate-amyloid-beta antibody program
STOCKHOLM, Dec. 19, 2024 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that it has entered into a global exclusive license agreement with Bristol Myers Squibb (NYSE: BMY) for BioArctic's PyroGlutamate-amyloid-beta (PyroGlu-Aβ) antibody program, including BAN1503 and BAN2803, whereof the latter includes BioAr...
2
4
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
NOTE!
1. NFA
2. Do not open position without chart confirmation, indicators, momentum.
3. Check current shorts availability on FINTEL.io
4. Scale out and secure profits
5. Always remember shorts include dark pools.
6. Most importantly, don’t blame for your losses. I already give watchlist and stock education. The ball is on you.
7. I DO NOT give buy or sell advice
8. COH (cash on hand); AH (after hours): RTH (regular trading hours)
$Currenc Group (CURR.US)$ Despac Sk...
1. NFA
2. Do not open position without chart confirmation, indicators, momentum.
3. Check current shorts availability on FINTEL.io
4. Scale out and secure profits
5. Always remember shorts include dark pools.
6. Most importantly, don’t blame for your losses. I already give watchlist and stock education. The ball is on you.
7. I DO NOT give buy or sell advice
8. COH (cash on hand); AH (after hours): RTH (regular trading hours)
$Currenc Group (CURR.US)$ Despac Sk...
57
38
11
$BioAge Labs (BIOA.US)$ good deal
$BioAge Labs (BIOA.US)$ BioAge Labs Announces Multi-Year Collaboration With Novartis To Discover Novel Targets For Therapies That Address Age-Related Diseases And Conditions; Novartis To Pay Up To $20M Comprising Upfront Payments And Research Funding; BioAge May Receive Up To $530M In Future Long-Term Research, Development, And Commercial Milestones
Collaboration will leverage BioAge's differentiated human longevity data and platform and Novartis expertise in the biology of physical exercise ...
Collaboration will leverage BioAge's differentiated human longevity data and platform and Novartis expertise in the biology of physical exercise ...
3
No comment yet
Heat List
US
Overall
Symbol
Price
% Chg
No Data
JimyJimy : can we run this up today
the MONEY drifter : lot of good news with this candidate. It's already on my watchlist today
Stock_Drift OP JimyJimy : Let’s hope so!!
